Cagrilintide Side Effects: 7 Things to Watch For (and How to Manage Them)

Cagrilintide at a glance:

• Drug class: Long-acting amylin analog
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Receptor target: amylin receptors (calcitonin receptor + RAMP)

Side effects are the single biggest reason people quit Cagrilintide during the first eight weeks. Most of them are predictable and most of them improve. Knowing which is which up front makes the difference.

Common Side Effects of Cagrilintide

The side effects most often reported with Cagrilintide:

• Nausea — most common in the first 4-8 weeks of titration; usually improves with smaller meals and slower eating.
• Decreased appetite — this is the intended effect for weight-loss indications, but may feel uncomfortable initially.
• Diarrhea — often dose-related; hydration and a temporarily lower-fiber diet can help.

These tend to be dose-related. They are most prominent during dose escalation and typically improve once the body adapts to a steady dose.

Serious Risks

Less common but important:

• Limited long-term data — see the prescribing information for full risk language for details. Notify your clinician promptly if relevant symptoms develop.

How to Manage Common Side Effects

Slow titration. Most GI side effects appear during dose increases. Holding each step for at least four weeks before moving up reduces both severity and dropout rates.

Eat smaller meals. Delayed gastric emptying is a feature of these medications, not a bug. Smaller, more frequent meals are easier to tolerate than three large ones.

Hydrate aggressively. Dehydration worsens nausea and is the most common driver of acute kidney injury reports.

Avoid greasy or fried foods early on. They sit longer and amplify nausea.

Anti-nausea medications. Ondansetron and similar agents are commonly prescribed bridging tools during the first weeks.

Don't lie down right after eating. It worsens reflux symptoms, which are common in early treatment.

For dose-titration questions, see our Cagrilintide dosage guide.

Side Effects vs. Withdrawal Effects

It's worth distinguishing between side effects (from taking the drug) and withdrawal or rebound effects (from stopping it). For Cagrilintide, the most relevant rebound concern is appetite returning to baseline and weight regain when the medication is discontinued, which has been documented in trial extension data.

When to Stop and Call Someone

These symptoms warrant prompt clinical evaluation:

• Severe abdominal pain (especially radiating to the back) — possible pancreatitis
• Vision changes
• Signs of allergic reaction (hives, throat tightness, difficulty breathing)
• Severe vomiting or dehydration
• Persistent symptoms that worsen rather than improve

Side Effects in Context

Most people who take Cagrilintide experience some side effects. Most of those are tolerable and improve with time. The decision to continue is a balance between benefit and tolerance, made together with a clinician.

For people weighing whether Cagrilintide is the right fit, our Cagrilintide results page covers the upside.

Bottom Line

Most Cagrilintide side effects improve with time at a steady dose. The minority that don't usually have a management strategy worth trying before stopping the drug.

Frequently Asked Questions

Related Reading

• The Honest Guide to Cagrilintide: What Patients and Doctors Actually Say
• Cagrilintide Results: Realistic Expectations vs. Trial Headlines
• Why Cagrilintide Costs So Much (and 5 Ways to Pay Less)
• Cagrilintide and Weight Loss: What Trials Show vs. Real Life
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.

This page is informational only and is not medical advice. Stop Cagrilintide and seek medical attention if you experience severe symptoms.